Board Members

Dr John Schubert PhD, Chairman of the Board Dr Schubert's distinguished senior corporate management career includes five years as Chairman and Managing Director of Esso Australia Ltd, six years as Managing Director and CEO of Pioneer International Limited and extensive Board representation. Dr Schubert is Chairman of the Commonwealth Bank of Australia. He is a director of BHP-Billiton Limited, BHP-Billiton Plc, the Worley Group Limited, Qantas Airways Limited and the Great Barrier Reef Research Foundation.

Professor Charles Mackay, Founder and Director Professor Mackay leads the company's Inflammation programmes, and brings extensive experience in inflammation and immunology generally and in raising antibodies to chemo-attractant receptors specifically. A significant proportion of all such antibodies world-wide were either raised by Professor Mackay, or by alumni of his lab. Professor Mackay is Head of the Immunology and Inflammation Programme at the Garvan, and holds an academic appointment at the University of NSW.

Professor John Shine AO, PhD, Director Professor Shine is the Executive Director, Garvan Institute of Medical Research, Professor of Medicine and Professor of Molecular Biology at the University of New South Wales. He is also currently Chair of the National Health and Medical Research Council and Secretary (Biological Sciences) of the Australian Academy of Science. Professor Shine is an Australian molecular biology and biotechnology pioneer; his scientific achievements include the discovery of fundamental RNA translation signals, including the "Shine-Dalgarno sequence". He was also a member of the team which cloned the first human gene and first biotechnology product of insulin as as the genes for human growth hormone, galanin and relaxin.

Mr James Wentworth, Director Mr Wentworth is an Associate Director of CHAMP Ventures Pty Limited and is also an Alternate Director of Rogen International Limited, Maxamine, Inc and Kailis & France Foods Pty Ltd. Prior to joining CHAMP Ventures he worked in Goldman Sachs' Principal Investment Area in New York. Mr Wentworth has over 9 years experience in private equity and corporate finance in Australia, New Zealand and New York. Mr Wentworth holds both a Bachelor of Commerce and a Bachelor of Law (Honours) from Queensland University and is admitted to practice as a solicitor.

Mr Andrew Adamovich, Director Andrew Adamovich is a Founder and Director of Riverland Capital Limited, Director of Amara Enterprises Limited, Yuan Chuan (Cayman) Limited, China Education Corporation, and ASX-listed Ambition Group Limited. Previously Andrew was an Associate with the Zurich Centre Group and a Director at Equity Partners Asia Limited. Mr. Adamovich has over ten years experience in finance, focused on direct investment in Asia. Mr. Adamovich has a Bachelor of Arts degree from the University of California, Berkeley, USA.

Senior Scientific Staff

Dr Peter Whitfeld, Scientific Project Manager Dr Whitfeld has over 20 years experience in biotechnology research, development and project management. He is the Manager for the C5aR program at G2 Therapies. He leads a team of research staff in the molecular biology, assay development, antibody production and testing areas. Dr Whitfeld is also a senior staff member in the Immunology and Inflammation Research Program at the Garvan Institute of Medical Research. Prior to joining G2 and the Garvan, Dr Whitfeld held senior research and managerial positions at GroPep and Biotech Australia. He held post doctoral research positions at CSIRO, Fox Chase Cancer Center and Prince Henrys Institute for Medical Research after completing a PhD at the Australian National University, Research School of Biological Sciences.